Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYXOTCMKTS:AKSYOTCMKTS:WWINOTCMKTS:XCRP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00$0.00▼$0.00N/A2.05N/AN/AAKSYAksys$0.00$0.00▼$0.00N/AN/AN/AN/AWWINAllyMe Group$0.00$7.25▼$70.00N/AN/A133 shs100 shsXCRPXcorporeal$0.00$0.00▼$0.00N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AKSYAksys0.00%0.00%0.00%0.00%0.00%WWINAllyMe Group0.00%0.00%0.00%0.00%0.00%XCRPXcorporeal0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/AN/AN/AN/AN/AN/AN/AXCRPXcorporealN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAlliqua BioMedical 0.00N/AN/AN/AAKSYAksys 0.00N/AN/AN/AWWINAllyMe Group 0.00N/AN/AN/AXCRPXcorporeal 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/AN/AN/AN/AN/AXCRPXcorporealN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAlliqua BioMedicalN/AN/A0.00N/AN/AN/AN/AN/AN/AAKSYAksysN/AN/A0.00N/AN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/A0.00N/AN/AN/AN/AN/AN/AXCRPXcorporealN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAlliqua BioMedicalN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/AN/AN/AN/AXCRPXcorporealN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAlliqua BioMedicalN/AAKSYAksysN/AWWINAllyMe GroupN/AXCRPXcorporealN/AInsider OwnershipCompanyInsider OwnershipADYXAlliqua BioMedical17.40%AKSYAksys3.80%WWINAllyMe GroupN/AXCRPXcorporealN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAlliqua BioMedical6N/AN/ANot OptionableAKSYAksys87N/AN/ANot OptionableWWINAllyMe GroupN/AN/AN/ANot OptionableXCRPXcorporeal24N/AN/ANot OptionableXCRP, ADYX, AKSY, and WWIN HeadlinesRecent News About These CompaniesWhy is XRP price up today?October 17, 2024 | cointelegraph.comXRP Licks Wound After Dollar Rally Triggers Crypto CrashSeptember 24, 2024 | fxempire.comFXRP News Today: SEC v Ripple Lawsuit Settlement Prospects and ForecastSeptember 21, 2024 | fxempire.comFXRP News Today: Appeal Speculation Pushes XRP Higher – Will the Rally Last?September 18, 2024 | fxempire.comFRipple (XRP) Price Analysis: What Next for XRP after This $2 Billion CorrectionSeptember 18, 2024 | fxempire.comFXRP Price Enters 3-Day Winning Streak as Ripple Co-Founder Backs Kamala HarrisSeptember 11, 2024 | fxempire.comFXRP dips to $0.52, Ripple reserve on Binance down by whopping 167 million since JulySeptember 11, 2024 | fxstreet.comThe Separation of Ripple and XRP: Why it Happened? What Does it Mean and What are the Differences?August 31, 2024 | fxempire.comFXRP NewsAugust 30, 2024 | investing.comRipple price is poised for a decline as on-chain metrics show a negative trendAugust 30, 2024 | fxstreet.comXRP News Today: Kraken Ruling Boosts Confidence, But XRP Remains Below Key LevelsAugust 27, 2024 | fxempire.comFRipple price is set for a rally as on-chain data shows a positive biasAugust 23, 2024 | fxstreet.comRIPPLE NEWS, ANALYSIS AND FORECASTAugust 21, 2024 | fxstreet.comRipple rallies on hope of lawsuit win, XRP extends gains to $0.65August 2, 2024 | fxstreet.comXRP News Today: Legal Battle Intensifies as SEC Counters Ripple’s Motion to StrikeJuly 31, 2024 | fxempire.comFXRP News Today: Legal Expert and Ex-SEC Official Say No to SEC AppealJuly 28, 2024 | fxempire.comFXRP News Today: Ripple Benefits from SEC’s ETF Decision; Eyes on Coinbase AppealMay 27, 2024 | fxempire.comFXRP Falls Short of $0.40 as Investors Await SEC v Ripple Court RulingMay 26, 2024 | fxempire.comFXRP Price Finds Footing Ahead of Key Regulatory DeadlineMay 26, 2024 | fxempire.comFXRP News Today: SEC Appeal Plans Threaten XRP Price StabilityMay 19, 2024 | fxempire.comFXCRP, ADYX, AKSY, and WWIN Company DescriptionsAlliqua BioMedical OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Aksys OTCMKTS:AKSYAksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient's blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters. It also evaluates the performance of the artificial kidney in removing toxins from the patient's blood prior to each treatment, as well as automatically evaluates the water treatment filters and indicates whether a replacement is required and verifies that safety systems, sensors, and alarms are operating correctly. Aksys Ltd. also provides various services, including the delivery and installation of the PHD System; technical services, including maintenance and repair of the PHD System; delivery of consumables used in dialysis, such as the water purification components and dialysate concentrate; and artificial kidney, and arterial and venous blood tubing. The company markets its products and services, primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups in the United States, the United Kingdom, and Japan. Aksys Ltd. was founded in 1991 and is headquartered in Lincolnshire, Illinois.AllyMe Group OTCMKTS:WWINAllyme Group, Inc. engages in providing consulting services in China principally focused on the development of new-high-tech products marketing and retail sales. It seeks to provide management advisory services to business organizations worldwide. The company intends to assist smaller developing companies in the development of business models and strategies. It offers business, marketing, financial consultancy and business modelling support to its client organizations. The company was founded on August 13, 2014 and is headquartered in Los Angeles, CA.Xcorporeal OTCMKTS:XCRPXcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
